Repligen (RGEN) Tops Q3 EPS by 10c ; Offers Guidance

Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.43, $0.10 better than the analyst estimate of $0.33. Revenue for the quarter came in at $155 million versus the consensus estimate of $153.22 million.

GUIDANCE:

Repligen sees FY2024 EPS of $1.50-$1.58, versus the consensus of $1.49. Repligen sees FY2024 revenue of $630-639 million, versus the consensus of $629.7 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• BofA Securities Downgrades Smith & Nephew PLC. (SN:LN) (SNN) to Neutral
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight